Company news
Natera, Inc. (NASDAQ:NTRA) news
Every Natera, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
August 28, 2026
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
August 27, 2026
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
August 12, 2026
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
August 5, 2026
Natera to Report its Second Quarter Results on August 6, 2026
July 30, 2026
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
July 22, 2026
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
July 16, 2026
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
July 9, 2026
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
July 6, 2026
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
June 29, 2026
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
June 24, 2026
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
June 23, 2026
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
June 18, 2026
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Col...
June 4, 2026
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
June 3, 2026
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
May 29, 2026
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
May 28, 2026
Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
May 27, 2026
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
May 26, 2026
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
May 21, 2026
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
May 21, 2026
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
May 20, 2026
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
May 15, 2026
Natera Reports First Quarter 2026 Financial Results
May 7, 2026
Natera to Report its First Quarter Results on May 7, 2026
April 30, 2026
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
April 22, 2026
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
April 13, 2026
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
April 9, 2026
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
April 7, 2026
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
March 31, 2026
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
March 16, 2026
Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis
March 13, 2026
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
March 12, 2026
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
March 12, 2026
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
February 27, 2026
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
February 24, 2026
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
February 17, 2026
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
February 6, 2026
Natera Submits Signatera™ CDx PMA to FDA
February 2, 2026
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
January 28, 2026
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
January 26, 2026
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
January 21, 2026
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine ...
January 20, 2026
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
January 13, 2026
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
January 12, 2026
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
January 11, 2026
Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board
January 8, 2026
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 7, 2026
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
January 6, 2026